56 87

Cited 1 times in

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma

DC FieldValueLanguage
dc.contributor.author김진석-
dc.date.accessioned2018-11-23T11:33:34Z-
dc.date.available2018-11-23T11:33:34Z-
dc.date.issued2017-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/165810-
dc.description.abstractBortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM.Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS).Thirty-nine (22%) patients were aged ≥ 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. ≥ 2; p = 0.0002), β2-microglobulin level (< 5.5 vs. ≥ 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. ≥ 35.1 mg/m2; p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP.In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherImpact Journals-
dc.relation.isPartOfONCOTARGET-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHAsian Continental Ancestry Group-
dc.subject.MESHBortezomib/administration & dosage-
dc.subject.MESHBortezomib/adverse effects-
dc.subject.MESHDiarrhea/chemically induced-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMale-
dc.subject.MESHMelphalan/administration & dosage-
dc.subject.MESHMelphalan/adverse effects-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultiple Myeloma/drug therapy*-
dc.subject.MESHMultiple Myeloma/ethnology-
dc.subject.MESHMultiple Myeloma/pathology-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHNeutropenia/chemically induced-
dc.subject.MESHPrednisone/administration & dosage-
dc.subject.MESHPrednisone/adverse effects-
dc.subject.MESHProspective Studies-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHTreatment Outcome-
dc.titleA prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMin Kyoung Kim-
dc.contributor.googleauthorKihyun Kim-
dc.contributor.googleauthorChang-Ki Min-
dc.contributor.googleauthorJae-Yong Kwak-
dc.contributor.googleauthorSang-Byung Bae-
dc.contributor.googleauthorSung-Soo Yoon-
dc.contributor.googleauthorJe-Jung Lee-
dc.contributor.googleauthorKi Hwan Kim-
dc.contributor.googleauthorSeung-Hyun Nam-
dc.contributor.googleauthorYeung-Chul Mun-
dc.contributor.googleauthorHyo Jung Kim-
dc.contributor.googleauthorSung Hwa Bae-
dc.contributor.googleauthorHo-Jin Shin-
dc.contributor.googleauthorJung-Hee Lee-
dc.contributor.googleauthorJoon Seong Park-
dc.contributor.googleauthorSeong Hyun Jeong-
dc.contributor.googleauthorMark Hong Lee-
dc.contributor.googleauthorYang-Soo Kim-
dc.contributor.googleauthorHo Sup Lee-
dc.contributor.googleauthorKeon Woo Park-
dc.contributor.googleauthorWon-Sik Lee-
dc.contributor.googleauthorSang Min Lee-
dc.contributor.googleauthorJeong-Ok Lee-
dc.contributor.googleauthorMyung Soo Hyun-
dc.contributor.googleauthorDeog Yeon Jo-
dc.contributor.googleauthorSung-Nam Lim-
dc.contributor.googleauthorJae Hoon Lee-
dc.contributor.googleauthorDo-Yeun Cho-
dc.contributor.googleauthorYoung Rok Do-
dc.contributor.googleauthorJeong-A Kim-
dc.contributor.googleauthorSeong Kyu Park-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorSoo-Jeong Kim-
dc.contributor.googleauthorHawk Kim-
dc.contributor.googleauthorHyeon Gyu Yi-
dc.contributor.googleauthorJoon Ho Moon-
dc.contributor.googleauthorChul Won Choi-
dc.contributor.googleauthorSung-Hyun Kim-
dc.contributor.googleauthorYoung-Don Joo-
dc.contributor.googleauthorHoon-Gu Kim-
dc.contributor.googleauthorByung Soo Kim-
dc.contributor.googleauthorMoo-Rim Park-
dc.contributor.googleauthorMoo-Kon Song and Su-Youn Kim-
dc.identifier.doi10.18632/oncotarget.16790-
dc.contributor.localIdA01017-
dc.relation.journalcodeJ02421-
dc.identifier.eissn1949-2553-
dc.identifier.pmid28402945-
dc.subject.keywordaged-
dc.subject.keywordbortezomib-
dc.subject.keywordcombination-
dc.subject.keyworddrug therapy-
dc.subject.keywordmultiple myeloma-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.affiliatedAuthor김진석-
dc.citation.volume8-
dc.citation.number23-
dc.citation.startPage37605-
dc.citation.endPage37618-
dc.identifier.bibliographicCitationONCOTARGET , Vol.8(23) : 37605-37618, 2017-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.